Author

Christine S Barker

Observed name: Christine Barker

Institution: Children's Hospital of Philadelphia

Observed institutions: Children's Hospital of Philadelphia, Pharmacyclics (United States)

OpenAlex ID: A5034496289

Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.

2016 · Shannon L. Maude, David T. Teachey, et al. · Journal of Clinical Oncology · 149

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

2015 · Susan R. Rheingold, Lanyi Nora Chen, et al. · Blood · 44

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

2015 · Shannon L Maude, David M. Barrett, et al. · Blood · 29

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

2017 · Shannon L. Maude, George Hucks, et al. · Blood · 24

A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.

2013 · John C. Byrd, Jacqueline Claudia Barrientos, et al. · Journal of Clinical Oncology · 14

Works count: 5

Citation count: 260

H-index: 5

I10-index: 5